Page last updated: 2024-08-23

valrubicin and Acute Myelogenous Leukemia

valrubicin has been researched along with Acute Myelogenous Leukemia in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19902 (66.67)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gahrton, G; Peterson, C; Vitols, S1
Kanter, PM; Schwartz, HS1
Larsson, BS; Mårs, U; Masquelier, M; Pålsson, M; Peterson, CO; Vitols, S1

Other Studies

3 other study(ies) available for valrubicin and Acute Myelogenous Leukemia

ArticleYear
Significance of the low-density lipoprotein (LDL) receptor pathway for the in vitro accumulation of AD-32 incorporated into LDL in normal and leukemic white blood cells.
    Cancer treatment reports, 1984, Volume: 68, Issue:3

    Topics: Aged; Doxorubicin; Female; Humans; Kinetics; Leukemia, Myeloid, Acute; Leukocytes; Lipoproteins, LDL; Male; Middle Aged; Receptors, Cell Surface; Receptors, LDL

1984
DNA damage by anthracycline drugs in human leukemia cells.
    Cancer letters, 1981, Volume: 13, Issue:4

    Topics: Carubicin; Cells, Cultured; Daunorubicin; DNA Repair; DNA, Neoplasm; Doxorubicin; Drug Evaluation; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Prognosis

1981
Low density lipoprotein as a carrier of cytostatics in cancer chemotherapy: study of stability of drug-carrier complexes in blood.
    Journal of drug targeting, 2000, Volume: 8, Issue:3

    Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Doxorubicin; Drug Carriers; Female; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lipoproteins, LDL; Male; Mice; Mice, Inbred BALB C; Middle Aged; Paclitaxel

2000